COVID-19 Medtech Lessons: Data Point To ‘Healthy Industry In An Unhealthy Time’ But Business Models Must Change
Executive Summary
Ernst &Young’s annual Pulse of the Industry report says strong R&D spending by medtechs in 2019 bodes well for their post-pandemic recovery as industry leaders point to long-term changes to the industry that companies must navigate when future-proofing their business models.
You may also be interested in...
J&J Bounces Back In Q3, Led By Interventional Devices
Johnson & Johnson’s worldwide medical device revenues grew about 50% sequentially in the third quarter to $6.2bn.
Report Digest: Discussing What's Going On With Prostate Cancer Diagnosis And Treatment
In this edition of Report Digest, UK-based reporter Barnaby Pickering talks about the prostate cancer diagnostics and minimally invasive treatments markets with analyst Phil Greenfield. The two discuss ongoing developments in both treatment and diagnosis, while exploring driving and limiting factors for both.
Using Digital Tools To Unpick The Adherence Problem
An ambitious five-year public-private partnership plans to tackle non-adherence to medicines by giving patients EU-wide access to regulator-approved digital drug information. One year in, progress has been made in creating an app that could do just this.